NCT03757325View on ClinicalTrials.gov

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

December 5, 2019

Study Completion Date

December 5, 2019

Conditions
Alzheimer Disease
Interventions
DRUG

DNL747

DNL747

DRUG

Placebo

Placebo

Trial Locations (5)

9713

Clinical Site(s), Groningen

32806

Clinical Site(s), Orlando

33143

Clinical Site(s), Miami

75231

Clinical Site(s), Dallas

84124

Clinical Site(s), Salt Lake City

Sponsors
All Listed Sponsors
lead

Denali Therapeutics Inc.

INDUSTRY

NCT03757325 - Study to Evaluate DNL747 in Subjects With Alzheimer's Disease | Biotech Hunter | Biotech Hunter